-
Product Insights
NewLikelihood of Approval Analysis for Systemic Lupus Erythematosus
Overview How likely is it that the drugs in Systemic Lupus Erythematosus will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Systemic Lupus Erythematosus Overview Systemic Lupus Erythematosus (SLE) is a chronic...
-
Product Insights
NewLikelihood of Approval Analysis for Lupus Erythematosus
Overview How likely is it that the drugs in Lupus Erythematosus will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lupus Erythematosus Overview Lupus erythematosus refers to a group of autoimmune diseases...
-
Product Insights
NewLikelihood of Approval Analysis for Lupus Nephritis
Overview How likely is it that the drugs in Lupus Nephritis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lupus Nephritis Overview Lupus nephritis is a severe complication of systemic lupus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Hypoxic-Ischemic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Hypoxic-Ischemic Encephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Hypoxic-Ischemic Encephalopathy Drug Details: RLS-0071 (PIC1-01) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6382 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6382 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6382 in Systemic Lupus Erythematosus Drug Details: RO-7507062 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Systemic Lupus Erythematosus Drug Details: VNX-01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Systemic Sclerosis (Scleroderma) Drug Details: VNX-01 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Dermatomyositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Dermatomyositis Drug Details: VNX-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VENT-03 in Neuroinflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VENT-03 in Neuroinflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VENT-03 in Neuroinflammation Drug Details: VNX-01 is under development for the treatment of...